Related Experiment Video
Updated: Jan 11, 2026
03:07
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
793
A Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for
Lejla Hadzikadic-Gusic1, Jessica Bilz1, Danielle Boselli2
1Department of Surgery, Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Annals of Surgery
|November 12, 2025
Summary
Radioactive seed localization (RSL) is a viable alternative to wire-guided localization (WL) for nonpalpable breast cancer, offering improved patient and provider satisfaction without compromising margin rates. This study highlights RSL
Area of Science:
- Oncology
- Radiology
- Surgical Procedures
Background:
- Wire-guided localization (WL) is standard for nonpalpable breast tumors.
- Limited randomized controlled trials compare localization techniques.
- Radioactive seed localization (RSL) is an emerging alternative.
Purpose of the Study:
- To compare radioactive seed localization (RSL) and wire-guided localization (WL).
- To evaluate efficacy and patient experience in nonpalpable malignant breast disease treatment.
Main Methods:
- Randomized controlled trial of 400 women with nonpalpable malignant breast disease.
- Comparison of RSL versus WL, stratified by surgeon and invasive disease status.
- Primary outcome: initial resection negative margin rates; Secondary outcomes: time, cost, satisfaction.
Main Results:
- No significant difference in negative margin rates between RSL and WL (P=0.29).
- RSL showed improved patient satisfaction scores for anxiety, pain, and overall experience (P<0.01).
- RSL offered better convenience and satisfaction for radiologists and surgeons (P<0.01), despite a higher cost.
Conclusions:
- Radioactive seed localization (RSL) is an acceptable alternative to wire-guided localization (WL).
- RSL improves patient and provider satisfaction.
- RSL does not compromise negative margin achievement in nonpalpable malignant breast disease.
